Pharmaceutical Juno-B (02126) announced interim results. The loss during the period of 504.26 million yuan decreased by 81.13% year-on-year

According to the Zhitong Finance App, Yao Ming Junuo-B (02126) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 111 million (same unit), an increase of 4.71% over the previous year; loss of 504.26 million yuan during the period, a year-on-year decrease of 81.13%; and a loss of 0.12 yuan per share.

According to the announcement, the loss reduction was mainly due to: (i) no impairment expenses were confirmed in the current period, and an impairment loss of $153 million was confirmed for the JWATM204/214 license during the same period of the previous year; (ii) due to the continued strengthening of RMB against the US dollar and Hong Kong dollar, unrealized exchange earnings from offshore companies within the group converted the transaction currency (RMB) into functional currencies (US dollars and Hong Kong dollars) generated net exchange earnings; (iii) the total revenue generated by sales of Benodat® was increased while sales rates were better controlled; and (iv) received from Regeneron R&D in accordance with the cooperation agreement Hair Cost compensation led to a reduction in R&D expenses.